Cargando…

Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes

Treatment of differentiated thyroid cancer (DTC) is multidisciplinary and begins with surgical intervention. Often, radioactive iodine is used as the prototype targeted therapy to ablate any residual thyroid tissue or metastatic deposits. While these initial therapeutic modalities are often curative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roof, Logan, Geiger, Jessica L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105566/ https://www.ncbi.nlm.nih.gov/pubmed/37070083 http://dx.doi.org/10.2147/CMAR.S348711

Ejemplares similares

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
por: Hart, Christopher D, et al.
Publicado: (2013)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
por: Storandt, Michael H., et al.
Publicado: (2022)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
por: Shi, Bo, et al.
Publicado: (2022)

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020)

Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

The treatment landscape in thyroid cancer: a focus on cabozantinib
por: Weitzman, Steven P, et al.
Publicado: (2015)

SAT479 A Case of Thyroiditis Cause by Cabozantinib
por: Bulchandani, Sheetal, et al.
Publicado: (2023)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
por: Debaillon Vesque, Audrey, et al.
Publicado: (2020)

Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
por: Trojan, Jörg
Publicado: (2020)

Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2019)

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
por: Ito, Yasuhiro, et al.
Publicado: (2017)

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
por: Uche, An, et al.
Publicado: (2019)

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
por: Boustany, Johnny, et al.
Publicado: (2020)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
por: Iaxx, Romain, et al.
Publicado: (2022)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
por: Schwartz, Gabriel, et al.
Publicado: (2020)

Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma(1)
por: Sharma, Akanksha, et al.
Publicado: (2022)

A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
por: Kessler, Elizabeth R., et al.
Publicado: (2023)

Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma
por: Sharma, Akanksha, et al.
Publicado: (2023)

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
por: Yu, Steven S, et al.
Publicado: (2016)

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
por: Lheureux, Stephanie, et al.
Publicado: (2022)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer
por: Kumar, Shreya, et al.
Publicado: (2023)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
por: Kudo, Masatoshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ui8jfrem0vglb9d2bgcln2t3i